Exact Sciences Corporation has presented first-time clinical results for its Oncodetect molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC), showcasing a strong correlation between circulating tumor DNA (ctDNA) detection and recurrence risk following neoadjuvant therapy and surgery. The results, drawn from a 147-patient cohort in the NSABP B-59 substudy, were unveiled at the 2025 San Antonio Breast Cancer Symposium. The data indicated that MRD-positive patients had an approximately 30-fold higher risk of distant recurrence than MRD-negative patients, positioning Oncodetect as a potentially powerful prognostic tool in one of the most aggressive subtypes of breast cancer.

What this signals for molecular monitoring in TNBC post-surgery

The TNBC treatment landscape has long lacked robust, validated biomarkers to guide clinical decisions after surgery, particularly following neoadjuvant chemotherapy. Oncodetect’s results move this conversation forward by offering a highly stratified risk signal based on ctDNA status. With 95 percent of MRD-negative patients remaining recurrence-free at three years, the negative predictive value provides potential reassurance against overtreatment. Conversely, MRD-positive patients may represent a high-risk subgroup who could benefit from intensification strategies.

Industry observers view this as a step-change in post-surgical monitoring, especially since TNBC recurrence tends to occur early and aggressively. Unlike hormone receptor-positive breast cancers where long-term hormonal therapy offers ongoing risk mitigation, TNBC patients face compressed risk timelines. A test that can identify residual molecular disease could significantly alter clinical decision-making.

How Exact Sciences is positioning Oncodetect within its diagnostics pipeline

Exact Sciences has historically focused on screening and early detection with its Cologuard and Oncotype DX platforms. Oncodetect represents a more treatment-adjacent application, expanding the company’s reach into disease monitoring and potential therapy guidance. The company’s precision oncology division appears to be banking on MRD as its next frontier, with the TNBC data serving as a foundational milestone.

By selecting TNBC—a subtype with high unmet need and limited treatment personalization—for its first public data release, Exact Sciences is making a deliberate statement about Oncodetect’s role in high-risk oncology. While competitors have entered MRD spaces in lung, colorectal, and hematologic malignancies, relatively few have carved out a path in early breast cancer, and fewer still have trial-based post-surgical data in TNBC.

The results come from a nested substudy within the NSABP-B-59/GBG-96-GeparDouze clinical trial, which also evaluated immunotherapy (atezolizumab) in the neoadjuvant setting. This structure lends additional rigor to the MRD dataset and strengthens its clinical relevance.

Why the study design strengthens clinical and regulatory confidence

The NSABP B-59 substudy analyzed blood samples collected before therapy and after surgical resection in patients who had received standard neoadjuvant treatment, with or without atezolizumab. The follow-up period extended to a median of 37 months, enabling a relatively mature readout for recurrence-free survival based on MRD status.

A key differentiator in this study is the pre- and post-surgical comparison of ctDNA levels. ctDNA positivity fell from 95 percent before treatment to just 9 percent after therapy, demonstrating that Oncodetect can sensitively measure treatment response. Importantly, it is the post-surgical detection that carries the strongest prognostic signal. This focus aligns with how clinicians make decisions about adjuvant therapy and post-treatment surveillance.

Experts in breast oncology have pointed out that many MRD assays suffer from inadequate clinical trial anchoring, especially when used as laboratory-developed tests in retrospective settings. Exact Sciences, through its collaboration with the NSABP Foundation and the German Breast Group, appears to have sidestepped that issue.

What MolDx submission implies for payer strategy

Exact Sciences has stated its intention to submit the Oncodetect data to MolDx, a Medicare diagnostics program administered by Palmetto GBA. Securing coverage through MolDx is often a prerequisite for national adoption of molecular tests in oncology. However, reimbursement decisions typically require evidence of clinical utility in addition to prognostic value.

While the current study shows strong correlation between MRD status and outcomes, it does not yet demonstrate how treatment decisions based on Oncodetect results affect survival or recurrence. For instance, it remains unclear whether MRD-positive patients who receive escalated therapy fare better than those who do not. Without this utility layer, payers may hesitate to authorize routine use, even with impressive hazard ratios.

Nevertheless, regulatory analysts suggest that the combination of trial-embedded evidence, high negative predictive value, and defined high-risk population may make MolDx more receptive. The TNBC setting also offers less overlap with competing assays, which are often concentrated in colorectal or non-small cell lung cancer.

Why real-world adoption may face practical constraints

Assuming the test is reimbursed, adoption still depends on clinician education, workflow integration, and trust in MRD to guide therapy. Oncologists remain divided on how aggressively to treat MRD-positive patients in breast cancer, particularly when escalation options are limited or carry toxicity concerns.

Some clinicians have voiced concern that identifying residual disease without a clear therapeutic pathway may lead to anxiety and overtreatment. In TNBC, options are often limited to re-introducing chemotherapy or experimental approaches unless immune therapy was already deployed in the neoadjuvant phase.

Operationally, MRD testing demands logistical capacity for blood collection, sample transport, next-generation sequencing, and fast turnaround. While Exact Sciences has a proven laboratory network, expanding this for MRD testing will require investments in infrastructure and customer onboarding. Turnaround time becomes especially important when oncologists are making adjuvant therapy decisions in the short window following surgery.

How Oncodetect compares to other MRD platforms

Several MRD players are building portfolios across solid tumors, but few have targeted early TNBC with the same specificity. Natera’s Signatera has been evaluated in breast cancer, but primarily in hormone receptor-positive populations. Guardant Health’s Reveal platform and Foundation Medicine’s FoundationOne MRD are also expanding in breast and colorectal cancer, but comparative head-to-head data are lacking.

What sets Oncodetect apart is the clarity of its post-surgical focus, the strength of the hazard ratio, and the embedding within a randomized trial. The 30-fold increased risk in MRD-positive patients is among the highest reported in solid tumor MRD literature, though validation in a larger population remains necessary.

Exact Sciences is also advancing the NSABP B-64 prospective registry, which is enrolling 1,800 patients across all breast cancer subtypes. This may serve as a real-world validation platform for Oncodetect and expand its application beyond TNBC.

What future trials must address to drive clinical actionability

To transition from a prognostic tool to a clinical decision-making standard, Oncodetect must demonstrate that therapy decisions based on MRD status improve outcomes. Prospective interventional trials, where MRD-positive patients receive modified adjuvant regimens and are compared against standard follow-up, will be essential.

Until then, the test’s most immediate role may lie in identifying patients eligible for intensified monitoring or for inclusion in post-neoadjuvant clinical trials. If paired with a decision-support protocol, Oncodetect could help de-risk de-escalation strategies in MRD-negative patients, avoiding unnecessary treatment in a subgroup that already shows favorable prognosis.

The company has not publicly disclosed such trials, but regulatory watchers believe that a utility-based registry or prospective adaptive study is likely on the roadmap, particularly if MolDx coverage is granted.

  breast cancer diagnostics, ctDNA, Exact Sciences, MolDx, molecular residual disease, MRD testing, NSABP B-59, Oncodetect, SABCS, triple-negative breast cancer